Neuroprotective effect of riluzole in MPTP-treated mice.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Brain Research

• Publication date

  2001-11-09

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0006-8993(01)02944-4PMID 11684056
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse.

  2001cited by this paper
• Protective Effects of Riluzole on Dopamine Neurons

  2000cited by this paper
• The Non‐NMDA Glutamate Receptor Antagonists 6‐Cyano‐7‐Nitroquinoxaline‐2,3‐dione and 2,3‐Dihydroxy‐6‐Nitro‐7‐Sulfamoylbenzo(f)quinoxaline, but Not NMDA Antagonists, Block the Intrastriatal Neurotoxic Effect of MPP+

  1999cited by this paper
• Antioxidative and Proapoptotic Effects of Riluzole on Cultured Cortical Neurons

  1999cited by this paper
• Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP.

  1999cited by this paper
• Alteration of neurotensin receptors in MPTP-treated mice.

  1999cited by this paper
• Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model.

  1998cited by this paper
• Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat.

  1996cited by this paper
• Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study.

  1995cited by this paper
• A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.

  1994cited by this paper
• Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.

  1994cited by this paper
• Riluzole and experimental parkinsonism: partial antagonism of MPP+-induced increase in striatal extracellular dopamine in rats in vivo

  1994cited by this paper
• Characterization of the inhibitory mechanism of 1-methyl-4-phenylpyridinium and 4-phenylpyridine analogs in inner membrane preparations.

  1994cited by this paper
• The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP animal model of Parkinson's disease.

  1994cited by this paper
• NMDA antagonists partially protect against MPTP induced neurotoxicity in mice

  1993cited by this paper
• Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice.

  1992cited by this paper
• 1‐Methyl‐4‐Phenylpyridinium Produces Excitotoxic Lesions in Rat Striatum as a Result of Impairment of Oxidative Metabolism

  1992cited by this paper
• MK‐801 Fails to Protect Against the Dopaminergic Neuropathology Produced by Systemic 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine in Mice or Intranigral 1‐Methyl‐4‐Phenylpyridinium in Rats

  1992cited by this paper
• Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists

  1991cited by this paper
• Excitatory amino acids and neuropsychiatric disorders.

  1989cited by this paper
• 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--II. Biochemical properties.

  1985cited by this paper
• 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--I. Anticonvulsant properties.

  1985cited by this paper
• Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

  1985cited by this paper
• Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

  1984cited by this paper

• Chrysin for Neurotrophic and Neurotransmitter Balance in Parkinson's Disease.

  2024cites this paper
• The consequences of sleep deprivation on cognitive performance

  2023cites this paper
• Actaea racemosa L. Rhizome Protect against MPTP-Induced Neurotoxicity in Mice by Modulating Oxidative Stress and Neuroinflammation

  2022cites this paper
• Açai Berry Mitigates Parkinson’s Disease Progression Showing Dopaminergic Neuroprotection via Nrf2-HO1 Pathways

  2022cites this paper
• Discovery of Neuroprotective Agents Based on a 5-(4-Pyridinyl)-1,2,4-triazole Scaffold

  2022cites this paper
• Atrazine Inhalation Causes Neuroinflammation, Apoptosis and Accelerating Brain Aging

  2021cites this paper
• Atrazine Inhalation Worsen Pulmonary Fibrosis Regulating the Nuclear Factor-Erythroid 2-Related Factor (Nrf2) Pathways Inducing Brain Comorbidities.

  2021cites this paper
• Anti-inflammatory and Anti-oxidant Activity of Hidrox® in Rotenone-Induced Parkinson’s Disease in Mice

  2020cites this paper
• Antioxidants

  2020cites this paper
• Combined 1-Deoxynojirimycin and Ibuprofen Treatment Decreases Microglial Activation, Phagocytosis and Dopaminergic Degeneration in MPTP-Treated Mice

  2020cites this paper
• TLR4 absence reduces neuroinflammation and inflammasome activation in Parkinson's diseases in vivo model.

  2019cites this paper
• Chrysin restores MPTP induced neuroinflammation, oxidative stress and neurotrophic factors in an acute Parkinson's disease mouse model.

  2019cites this paper
• Potential new therapies against a toxic relationship: neuroinflammation and Parkinson's disease.

  2019cites this paper
• A simple method to study motor and non-motor behaviors in adult zebrafish.

  2019cites this paper
• Absence of a synergic nigral proapoptotic effect triggered by REM sleep deprivation in the rotenone model of Parkinson´s disease

  2019cites this paper
• Liver X receptors activation, through TO901317 binding, reduces neuroinflammation in Parkinson’s disease

  2017cites this paper
• Oxidative Stress and its Different Roles in Neurodegenerative Diseases

  2017cites this paper
• Neurotoxin 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Induced Animal Models of Parkinson’s Disease

  2017cites this paper
• Neuroprotective Effects of Temsirolimus in Animal Models of Parkinson’s Disease

  2017cites this paper
• MPTP Induces Systemic Parkinsonism in Middle-Aged Cynomolgus Monkeys: Clinical Evolution and Outcomes

  2016cites this paper
• Design, synthesis, biological evaluation and docking studies of sulfonyl isatin derivatives as monoamine oxidase and caspase-3 inhibitors

  2016cites this paper
• Translational drug discovery approaches targeting the PKD1 signaling in Parkinson's disease

  2016cites this paper
• Tricycloundecane Derivatives as Potential N‐Methyl‐D‐aspartate (NMDA) Receptor and Voltage‐Gated Calcium Channel Modulators

  2015cites this paper
• Protective Effects of Streblus asper Leaf Extract on H2O2-Induced ROS in SK-N-SH Cells and MPTP-Induced Parkinson's Disease-Like Symptoms in C57BL/6 Mouse

  2015cites this paper
• MPTP Neurotoxicity: Actions, Mechanisms, and Animal Modelling of Parkinson’s Disease

  2014cites this paper
• Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents.

  2014cites this paper
• Neurotoxin 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Animal Models for Parkinson's Disease

  2013cites this paper
• Neuroprotective Activities of Palmitoylethanolamide in an Animal Model of Parkinson's Disease

  2012cites this paper
• The behavioral performance tests of Mucuna pruriens gold nanoparticles in the 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine treated mouse model of Parkinsonism

  2012cites this paper
• Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP model.

  2012influential citation
• In silico docking reveals possible Riluzole binding sites on Nav1.6 sodium channel: implications for amyotrophic lateral sclerosis therapy.

  2012cites this paper
• Synthesis, evaluation and application of polycyclic fluorescent analogues as N-methyl-D-aspartate receptor and voltage gated calcium channel ligands.

  2011cites this paper
• Oxidative Stress in Neurodegenerative Diseases: Mechanisms and Therapeutic Perspectives

  2011cites this paper
• Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.

  2011cites this paper
• Chronic Administration with Rotenone does not Enhance MPTP Neurotoxicity in C57BL/6 Mice

  2010cites this paper
• Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson’s disease

  2010cites this paper
• Modulation of connexin 43 in rotenone-induced model of Parkinson's disease.

  2009cites this paper
• A Novel Anti-Parkinsonian Agent, Zonisamide, Attenuates MPTP-Induced Neurotoxicity in Mice

  2009cites this paper
• Poly(ADP‐ribose)polymerase inhibitor can attenuate the neuronal death after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced neurotoxicity in mice

  2009cites this paper
• Neuroprotection in Parkinson's disease.

  2009cites this paper
• Gender differences on MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in C57BL/6 mice.

  2009cites this paper
• A Novel Anti-Parkinsonian Agent, Zonisamide, Attenuates MPTP-Induced Neurotoxicity in Mice

  2009cites this paper
• Basal ganglia neuroprotection with anticonvulsants after energy stress: a comparative study

  2009cites this paper
• Systemic Administration of Proteasome Inhibitor Protects Against MPTP Neurotoxicity in Mice

  2009cites this paper
• Proteasome Inhibitor Does Not Enhance MPTP Neurotoxicity in Mice

  2008cites this paper
• Effects of estrogens on striatal damage after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in male and female mice.

  2008cites this paper
• Failure of acute administration with proteasome inhibitor to provide a model of Parkinson’s disease in mice

  2008cites this paper
• Driving GDNF expression: the green and the red traffic lights.

  2008cites this paper
• Protective effects of SUN N8075, a novel agent with antioxidant properties, in in vitro and in vivo models of Parkinson's disease.

  2008cites this paper
• In vitro and in vivo evidences that antioxidant action contributes to the neuroprotective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-nitroindazole.

  2008cites this paper
• Excitotoxicity.

  2007cites this paper
• Neuroprotection in Parkinson's disease: clinical trials.

  2007cites this paper
• Attenuation of 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine induced nigrostriatal toxicity in mice by N-acetyl cysteine.

  2007cites this paper
• Studies on the neurobehavioural toxic effects of the mitochondrial toxin, 3-nitropropionic acid

  2007cites this paper
• Award Number: W81XWH-05-1-0517 TITLE: Monitoring and counteracting functional deterioration in Parkinson's disease: A multilevel integrative approach in a primate model system PRINCIPAL INVESTIGATOR: Dr. Ingrid H.C.H.M. Philippens CONTRACTING ORGANIZATION: TNO Defense Safety and Security

  2006cites this paper
• Curcumin protects mouse brain from oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  2006cites this paper
• Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain.

  2006cites this paper
• Specific regulation of rat glial cell line‐derived neurotrophic factor gene expression by riluzole in C6 glioma cells

  2006cites this paper
• Time dependent alterations of co-localization of S100β and GFAP in the MPTP-treated mice

  2006cites this paper
• Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.

  2005cites this paper
• Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.

  2005cites this paper
• Effects of riluzole on combined MPTP + 3-nitropropionic acid-induced mild to moderate striatonigral degeneration in mice

  2005influential citation
• Neuroprotective effect of the angiotensin-converting enzyme inhibitor perindopril in MPTP-treated mice

  2004cites this paper
• Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease.

  2004cites this paper
• Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study.

  2004cites this paper
• Protective effect of pitavastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, on ischemia-induced neuronal damage

  2004cites this paper
• Pathogenesis of parkinson’s disease

  2004cites this paper
• Neuroprotective agents in Parkinson's disease: clinical evidence and caveats.

  2004cites this paper
• Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson's disease.

  2004cites this paper
• Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice.

  2004cites this paper
• A review of neuroprotective agents.

  2004cites this paper
• Endogenous Activation of mGlu5 Metabotropic Glutamate Receptors Contributes to the Development of Nigro-Striatal Damage Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in Mice

  2004cites this paper
• Expression of S‐100 protein is related to neuronal damage in MPTP‐treated mice

  2003cites this paper
• Cerebral alterations in a MPTP-mouse model of Parkinson’s disease – an immunocytochemical study

  2003influential citation
• Role of Dopamine Transporter Against MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) Neurotoxicity in Mice

  2003cites this paper
• Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease.

  2003cites this paper
• Neuroprotection in Parkinson disease.

  2003cites this paper
• Failure of estrogen to protect the substantia nigra pars compacta of female rats from lesion induced by 6-hydroxydopamine.

  2003cites this paper
• Screening of novel pentacyclo-undecylamines for neuroprotective activity.

  2003cites this paper
• Neuroprotection in Parkinson's disease: Clinical trials

  2003influential citation
• Effects of Ca2+ antagonists on motor activity and the dopaminergic system in aged mice.

  2003cites this paper
• Degenerative diseases Mild cognitive impairment: diagnosing Alzheimer's in the pre-dementia stage Related review: Mild cognitive impairment

  2002cites this paper
• Role of nitric oxide synthase against MPTP neurotoxicity in mice

  2002cites this paper